BioSpace News Archive

vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes (“T1D”), today reported financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments.

Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, announced its financial and operational results for the first quarter of its fiscal year 2024, which ended on June 30, 2023.